Health & Biotech
An Australian life science company that is the exclusive wholesale distributor for the EAORON branded skin care range to pharmacies, supermarkets and specialist retailers in Australia and New Zealand and owns, produces, designs and distributes its own range of consumer health products under the EZZ brand.
The Company has two distinct and synergistic business models: a wholesale distribution model for the EAORON branded products in the skin care segment; and an integrated model including development, production and distribution for the EZZ branded products in the consumer health segment. Synergy is created by selling the EZZ branded products to established distribution channels previously developed from selling the EAORON branded products
EZZ Life Science formulate, produce, market and distribute health supplements under the brand of EZZ, with a focus on products with significant demand from the market by consumers.
KEY PEOPLE
RELATED STOCKHEAD STORIES
News
Closing Bell: CPI reading shifts rate cut outlook; Tabcorp plunges 15pc while Felix Gold soars
Health & Biotech
EZZ lifts on record revenue of $66.4m in FY24
News
Closing Bell: ASX, Nikkei fight back; RBA refuses to budge on interest rates
Health & Biotech
ASX Health Stocks: Amplia sees new success in pancreatic cancer trial
News
Market Highlights: Not much spared on chopping block after another big selloff, Wall Street loses US$3.5 trillion
Health & Biotech
EZZ launches into ‘functional’ food market with four new products
Health & Biotech
Aussie made: ASX firms boosting local health & medical manufacturing
News
These ASX stocks are set to ride China’s market wave as trade relations warm
Health & Biotech
EZZ reports strong Q4 with customer receipts up 70pc to $23 million
Health & Biotech
Australia’s medical manufacturing sector – a global success story in the making
Health & Biotech
Check Up: Aussie biotech Ternarx to pioneer next-gen cancer medicine, and recent ASX health winners
Health & Biotech
EZZ launches EAORON products in Vietnam
Health & Biotech
ASX Health June Winners: Actinogen and Optiscan led a sector in good shape
Health & Biotech
The ASX biotechs with secured FDA clearances in 2024, and others looking likely
Stockhead TV
Break it Down: EZZ Life Science receives breakthrough FDA approval for food products
Health & Biotech
EZZ US bound after FDA approval for nine products
Health & Biotech